# Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

> **NCT06392009** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GRIN Therapeutics, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Tuberous Sclerosis Complex
- Focal Cortical Dysplasia

## Interventions

- **DRUG:** Radiprodil

## Key facts

- **NCT ID:** NCT06392009
- **Lead sponsor:** GRIN Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2026-06
- **Final completion:** 2028-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06392009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06392009, "Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06392009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*